SORIN uses KIKA's advanced EDC platform to evaluate effectiveness of Heart Valves

KIKA™ Clinical Solutions announced that SORIN Group is using KIKA's advanced EDC platform for clinical trial asset management on two open observational, multi-center, Real Life Registries to evaluate the effectiveness of SORIN Heart Valves.

“We're pleased that SORIN has continued to work with KIKA for their clinical trial needs and we're excited that they now have the opportunities Veracity™ offers to collect, protect and maximize their most important clinical asset - their data.”

KIKA provides the Veracity™ advanced EDC platform for Clinical Asset Management™ to the pharmaceutical, biotechnology and medical device industries.

SORIN Group is a global medical device company and a leader in the treatment of cardiovascular diseases. The Company develops, manufactures and markets medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders. With over 3,600 employees worldwide, the Group focuses on three major therapeutic areas: cardiopulmonary bypass; cardiac rhythm management; and, heart valve repair and replacement.

KIKA CEO Linda Beneze said, "We're pleased that SORIN has continued to work with KIKA for their clinical trial needs and we're excited that they now have the opportunities Veracity™ offers to collect, protect and maximize their most important clinical asset - their data."